Covid-19 Infection and Cardiovascular System: A-Review
Warda Mustfa1 and Hina Ayub2*
1PhD Scholar, Department of School of Space and Earth Science, University of Science and Technology of China, Hefei, Anhui, China
2BS Zoology, University of Narowal, Pakistan
*Corresponding Author: Hina Ayub, BS Zoology, University of Narowal, Pakistan.
Received: April 29, 2021; Published: June 08, 2021
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) affects the cells by ACE, leading to infect the human respiratory system severely. Recently investigated that COVID-19 also damage the Cardiovascular System, leading to cause severe myocardial injury. The increased mortality and morbidity in COVID-19 patients are mainly because of hypertension. This paper interprets the relationship between COVID-19 with cardiovascular damage, hypertension (HTN), ACE, blood pressure, CK-MB, and Lipid Profile. Hypertension (HTN) continues to be a strong and widespread risk factor for IHD.
Keywords: COVID-19; Cardiovascular Disease; Angiotensin-converting Enzyme; CoV-2; Hypertension; Blood Pressure
- Song Z., et al. “From SARS to MERS, thrusting coronaviruses into the spotlight”. Viruses 11 (2019): E59.
- Zhuo P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature (2020): 7.
- Pearson H., et al. “SARS: what have we learned?” Nature6945 (2003): 121-126.
- Drosten C., et al. “Identification of a novel coronavirus in patients with the severe acute respiratory syndrome”. The New England Journal of Medicine20 (2003): 1967-1976.
- World Health Organisation. “A cumulative number of reported probable cases of SARS” (2003).
- Enserink M. “The big question now: will it be back”. Science5631 (2003): 299.
- World Health Organisation. “Announcement of suspected SARS case in southern China” (2004).
- Lee N., et al. “A major outbreak of severe acute respiratory syndrome in Hong Kong”. The New England Journal of Medicine20 (2003): 1986-1994.
- Alexander LK., et al. “An experimental model for dilated cardiomyopathy after rabbit coronavirus infection”. Journal of Infectious Diseases 5 (1992): 978-985.
- Small JD., et al. “Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E”. American Journal of Pathology3 (1979): 709-729.
- Alexander LK., et al. “Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy”. Advances in Experimental Medicine and Biology 342 (1993): 365-370.
- Drazen JM. “SARS—looking back over the first 100 days”. The New England Journal of Medicine4 (2003): 319-320.
- Turner AJ., et al. “ACE2: from vasopeptidase to SARS virus receptor”. Trends in Pharmacology Science6 (2004): 291-294.
- Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
- Wong CK., et al. “Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome”. Clinical and Experimental Immunology 1 (2004): 95-103.
- Oudit GY., et al. “SARS coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS”. European Journal of Clinical Investigation 7 (2009): 618-625.
- Kreutz RE., et al. “Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 European Society of Hypertension COVID-19 Task Force Review of Evidence”. Cardiovascular Research (2019).
- Wu L., et al. “SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management”. Biochemistry Pharmacology 178 (2020): 114114.
- Nishiga M., et al. “COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives”. Nature Reviews Cardiology 17 (2020): 543-558.
- Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
- Landesberg G., et al. “Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery”. Journal of the American College of Cardiology9 (2003): 1547-54.
- Tabas I., et al. “Sub endothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications”. Circulation 16 (2007): 1832-1844.
- Hansson GK. “Inflammation, atherosclerosis, and coronary artery disease”. The New England Journal of Medicine 352 (2005): 1685-1695.
- Libby P and Simon DI. “Inflammation and thrombosis: the clot thickens”. Circulation 1003 (2001): 1718-1720.
- Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
- Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet (2020): S0140-6736 (20)305663.
- European Society of Cardiology. “Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers” (2020).
- American Heart Association. “HFSA/ACC/AHA statement addresses concern reusing RAAS antagonists in COVID-19” (2020).
- Crawford MH. “Chapter 6. Chronic ischemic heart disease”. In: Crawford MH, editor. Current diagnosis and treatment: cardiology,4e. New York: McGraw-Hill (2014).
- Mohrman DE and Heller L. “Chapter 1. Overview of the cardiovascular system”. In: Mohrman DE, Heller L, editors. Cardiovascular physiology, 8e. New York: McGraw-Hill (2014).
- Agbor-Etang BB and Setaro JF. “Management of Hypertension in Patients with Ischemic Heart Disease”. Current Cardiology Reports12 (2015): 119.
- Alhogbani T. “Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus”. Annals of Saudi Medicine 1 (2016): 78-80.
- Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
- Wu Q., et al. “Altered lipid metabolism in recovered SARS patients twelve years after infection”. Scientific Report 7 (2017): 9110.
- Zheng YY., et al. “COVID-19, and the cardiovascular system”. Nature Reviews Cardiology5 (2020): 259-260.
- Corrales-Medina VF., et al. “Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease”. JAMA 313 (2015): 264.
- J Wang H., et al. “Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care”. Brazilian Journal of Infectious Diseases 1 (2017): 12-18.
- Drazner MH. “The progression of hypertensive heart disease”. Circulation3 (2011): 327-334.
- Chhikara BS., et al. “Coronavirus SARS-CoV-2 disease COVID-19: Infection, prevention, and clinical advances of the prospective chemical drug therapeutics”. Chemical Biology Letters1 (2020): 63-72.
- Adedeji AO., et al. “Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms”. Journal of Virology14 (2013): 8017-8028.
- Wrap D., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 6483 (2020): 1260.
- Walls AC., et al. “Structure-function, and antigenicity of the SARS-CoV-2 spike glycoprotein”. Cell 181 (2020): 281-292.
- Joyce E., et al. “Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review”. European Heart Journal: Acute Cardiovascular Care 1 (2013): 77-83.
- Gurwitz D. “Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics”. Drug Development Research (2020).
- US FDA. Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™) (2020).
- Zhong Q., et al. “Antiviral activity of Arbidol against Coxsackievirus B5 in vitro and in vivo”. Archives of Virology 4 (2009): 601-607.
- Vankadari N. “Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein?” International Journal of Antimicrobial Agents 28 (2020): 105998.
- Reyskens KM and Essop MF. “HIV protease inhibitors and onset of cardiovascular diseases: A central role for oxidative stress and dysregulation of the ubiquitin-proteasome system”. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease2 (2014): 256-268.